AbbVie and Voyager Therapeutics to develop neurodegenerative disease therapies

AbbVie has announced a new drug research collaboration with Voyager Therapeutics, which will focus on the creation of new therapies for neurodegenerative diseases.

The exclusive strategic collaboration and option agreement will aim to develop and commercialise vectorised antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative conditions.

This work will combine AbbVie's monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager's gene therapy platform and expertise, allowing new adeno-associated viral vectors to be created.

Under the terms of the deal, Voyager will receive $69 million (GBP 49.5 million) as an upfront payment, and potentially up to $155 million in preclinical and phase I option payments, as well as development and regulatory milestone-based payments and royalties.

Dr Jim Sullivan, vice-president of pharmaceutical discovery at AbbVie, said: "This collaboration has the potential to address the needs of patients who live with conditions such as Alzheimer's disease, progressive supranuclear palsy and frontotemporal dementia."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.